News | July 30, 2024
GSK and Flagship partner to discover novel medicines and vaccines
GSK and Flagship to jointly fund up to $150 million upfront
GSK and Flagship to jointly fund up to $150 million upfront
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
Subscribe To Our Newsletter & Stay Updated
